Pharma Focus Europe

ERS Genomics and StemSight Enter into CRISPR/Cas9 Licensing Agreement

Thursday, January 18, 2024

ERS Genomics Limited, a company focused on CRISPR licensing and formed to facilitate broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, has entered into a non-exclusive CRISPR/Cas9 license agreement with StemSight Oy. StemSight is a biotechnology firm working on developing stem cell-based therapies for corneal blindness.

StemSight, a preclinical biotechnology company, is dedicated to creating off-the-shelf cell therapies to address unmet medical needs related to corneal blindness. The company originated as a spin-out from the laboratory of pluripotent stem cell pioneer Prof. Heli Skottman at Tampere University and is actively involved in innovative research in the field of regenerative medicine for the cornea.

Dr. Laura Koivusalo, CEO and Co-founder of StemSight, emphasized the significance of the partnership, stating, "This collaboration with ERS Genomics represents a significant advancement for StemSight. By leveraging the remarkable capabilities of CRISPR/Cas9, we aim to tackle major challenges in current allogeneic cell therapies, ultimately bringing us closer to life-changing treatments for patients with presently incurable blindness."

Eric Rhodes, CEO of ERS Genomics, highlighted the importance of adding StemSight to their list of licensees, emphasizing the growing influence of Finland and the Nordics in the global biotechnology and life science sector. He acknowledged StemSight's pioneering use of CRISPR/Cas9 technology to develop regenerative therapies for individuals suffering from limbal stem cell deficiency.

ERS Genomics, as a provider of CRISPR/Cas9 technology licensing, holds 89 patents in over 90 countries and offers licenses through its direct agreement with Emmanuelle Charpentier. The company now boasts nearly 150 licenses worldwide. The financial details of the agreement between ERS Genomics and StemSight have not been disclosed.

 

Source: businesswire.com


 

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva